<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>大叔快评 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-03T23:12:28+08:00</updated>
  <subtitle>肿瘤学临床研究及制药企业研发评述</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>吴一龙教授NEJM：奥希替尼治疗切除术后的EGFR突变型非小细胞肺癌</title>
    <updated>2020-11-03T23:02:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/jAvRb0ouLW8NswmlQdp6EA</id>
    <link href="https://mp.weixin.qq.com/s/jAvRb0ouLW8NswmlQdp6EA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CD30学院 | 周辉教授——弥漫大B细胞淋巴瘤治疗进展</title>
    <updated>2020-11-03T23:02:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/2tR55_tNSsNpBWzMzI0X1w</id>
    <link href="https://mp.weixin.qq.com/s/2tR55_tNSsNpBWzMzI0X1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田中国将亮相进博会：1000只千纸鹤的祝福</title>
    <updated>2020-11-02T15:20:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/25WhQzCURI0fOYWe9uqnDw</id>
    <link href="https://mp.weixin.qq.com/s/25WhQzCURI0fOYWe9uqnDw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田制药：未来要把15款以上创新药物引入中国</title>
    <updated>2020-11-01T11:52:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/V2gfqyTwvHWyjN9qNUPLIg</id>
    <link href="https://mp.weixin.qq.com/s/V2gfqyTwvHWyjN9qNUPLIg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>A+学院 | 王书杰教授：未来可期——纵览血友病诊疗新进展</title>
    <updated>2020-11-01T11:52:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/sXh41DovJ3gF7hjINRhdYQ</id>
    <link href="https://mp.weixin.qq.com/s/sXh41DovJ3gF7hjINRhdYQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>鲁比卡丁Lurbinectedin中文说明书</title>
    <updated>2020-11-01T11:52:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/lUFTxlMQscEhV8VGLppwXg</id>
    <link href="https://mp.weixin.qq.com/s/lUFTxlMQscEhV8VGLppwXg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>《第一声音》对话武田中国总裁单国洪</title>
    <updated>2020-10-28T21:46:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-28:/s/SA-6WTy2QC0eeZqPEjbJzQ</id>
    <link href="https://mp.weixin.qq.com/s/SA-6WTy2QC0eeZqPEjbJzQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【王景文教授点评】J Hematol Oncol | 复发HL、ALCL患者再次接受BV缓解率高及安全性可控</title>
    <updated>2020-10-28T17:51:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-28:/s/MffmORhA0SICOHC2vQ_6hQ</id>
    <link href="https://mp.weixin.qq.com/s/MffmORhA0SICOHC2vQ_6hQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>KRAS G12C抑制剂MRTX849和AMG510临床数据更新和比较</title>
    <updated>2020-10-26T22:18:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/veOWe9-ojoUbUnUv1xkYnw</id>
    <link href="https://mp.weixin.qq.com/s/veOWe9-ojoUbUnUv1xkYnw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药物警戒从幕后到前台，冲锋号已经吹响！</title>
    <updated>2020-10-26T22:18:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/pkYqUCBl4SDVitM9i75byQ</id>
    <link href="https://mp.weixin.qq.com/s/pkYqUCBl4SDVitM9i75byQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>真实世界数据研究用于药品及医疗器械的评价</title>
    <updated>2020-10-25T22:04:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-25:/s/zNFYzjblmg7nHUn0tf0ALw</id>
    <link href="https://mp.weixin.qq.com/s/zNFYzjblmg7nHUn0tf0ALw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【NACLC20】PD-1/PD-L1单抗治疗驱动基因阳性NSCLC的PFS差异</title>
    <updated>2020-10-25T22:04:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-25:/s/OlbCcrfsZEamOgD-WRMPtA</id>
    <link href="https://mp.weixin.qq.com/s/OlbCcrfsZEamOgD-WRMPtA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>智胜科技与医疗，共建数字化创新医疗生态圈</title>
    <updated>2020-10-23T08:41:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-23:/s/RuLpuQaqr6tyhO63MHuThg</id>
    <link href="https://mp.weixin.qq.com/s/RuLpuQaqr6tyhO63MHuThg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>钟立业教授解读 | 真实世界初治多发性骨髓瘤长程管理中PIs同类药物转换治疗可行性： US-MM6最新数据解读</title>
    <updated>2020-10-23T08:41:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-23:/s/o1E977ZYYt75s9z-l7s-Kw</id>
    <link href="https://mp.weixin.qq.com/s/o1E977ZYYt75s9z-l7s-Kw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田:维得利珠单抗（皮下注射剂型）维持治疗溃疡性结肠炎研究数据</title>
    <updated>2020-10-16T14:12:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-16:/s/-pb5VtRNKTp0IDUOaqD8ww</id>
    <link href="https://mp.weixin.qq.com/s/-pb5VtRNKTp0IDUOaqD8ww" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>奥希替尼联合抗血管生成单抗治疗EGFR T790M阳性晚期NSCLC</title>
    <updated>2020-10-15T22:04:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-15:/s/TPH5rFx1DUJGyja4IRnxEQ</id>
    <link href="https://mp.weixin.qq.com/s/TPH5rFx1DUJGyja4IRnxEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>多发性骨髓瘤患者细胞遗传学异常与疾病特征和治疗反应的相关性研究</title>
    <updated>2020-10-15T22:04:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-15:/s/18jPyPChPpXQL4DQ06NpNg</id>
    <link href="https://mp.weixin.qq.com/s/18jPyPChPpXQL4DQ06NpNg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>作为MA的您焦虑了吗？| 第五届CMAC国内药企年会圆满结束</title>
    <updated>2020-10-15T22:04:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-15:/s/SRvstNKMW96muguT1eoR8Q</id>
    <link href="https://mp.weixin.qq.com/s/SRvstNKMW96muguT1eoR8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>